BB Biotech Overview
- Founded
- 1993
- Status
- Public
- Stock Symbol
- BBZA
- Investments
- 60
- Share Price
- $94.03
- (As of Friday Closing)
BB Biotech General Information
Description
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the health care system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace.
Contact Information
Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Capital Markets/Institutions
Stock Exchange
FRA
Primary Office
- Schwertstrasse 6
- 8200 Schaffhausen
- Switzerland
+41 052 000 00 00
BB Biotech Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $94.03 | $91.47 | $53.34 - $94.51 | $5.2B | 4.47K | $12.31 |
BB Biotech Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2019 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 3,372,676 | 3,628,515 | ||
| Revenue | 731,595 | 731,595 | (433,126) | 741,498 |
| Net Income | 681,719 | 681,719 | (481,650) | 698,285 |
| Total Assets | 3,668,549 | 3,668,549 | 3,135,316 | 3,734,561 |
| Total Debt | 154,810 | 154,810 | 187,905 | 97,527 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
BB Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore BB Biotech‘s full profile, request access.
Request a free trialBB Biotech Executive Team (16)
BB Biotech Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000000 00.0 | The Medicines Company | Vice Chairman | 000 0000 |
| 00000 00000000 00.0 | Self | Chairman & President | 000 0000 |
| 00000 000000 00.0 | Self | Member of the Board of Directors | 000 0000 |
| 0000 00 00000 | BB Biotech | Board Member & Managing Director | 000 0000 |
BB Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore BB Biotech‘s full profile, request access.
Request a free trialBB Biotech Investments & Acquisitions (60)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 0000000000 | 01-Feb-2018 | 00000 00000 00 | 00000 | Drug Discovery | |
| 00000 | 06-Dec-2016 | 00000 00000 00 | 0000 | Therapeutic Devices | |
| 0000000 00000000 | 27-Oct-2016 | 000 | 00000 | Biotechnology | |
| 00000000 0000 0000 | 03-Sep-2015 | 00000 00000 00 | 000.00 | Drug Discovery | |
| Cidara Therapeutics | 11-Feb-2015 | Early Stage VC | 0000 | Biotechnology | 000 0000000 |
BB Biotech Exits (49)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 0000000000 | 01-Feb-2018 | 00000 00000 00 | 00000 | Completed |
|
| 00000000 0000 0000 | 03-Sep-2015 | 00000 00000 00 | 000.00 | Completed |
|
| 0000 000000000000 | 01-Aug-2014 | 00000 00000 00 | 00000 | Completed |
|
| 0000 000000000000 | 11-Mar-2014 | 00000 00000 00 | 0000 | Completed |
|
| Intracellular Therapies | 03-Sep-2013 | PIPE | 0000 | Completed |
|